Results from recent clinical trials of antibodies that target amyloid-β (Aβ) for Alzheimer's
disease have created excitement and have been heralded as corroboration of the amyloid …

Protein misfolding and aggregation is observed in many amyloidogenic diseases affecting
either the central nervous system or a variety of peripheral tissues. Structural and dynamic …

There is increasing appreciation that non-neuronal cells contribute to the initiation,
progression and pathology of diverse neurodegenerative disorders. This Review focuses on …

Tau and amyloid beta (Aβ) are the prime suspects for driving pathology in Alzheimer's
disease (AD) and, as such, have become the focus of therapeutic development. Recent …

The blood-brain barrier (BBB) prevents neurotoxic plasma components, blood cells, and
pathogens from entering the brain. At the same time, the BBB regulates transport of …

Animal models of human diseases that accurately recapitulate clinical pathology are
indispensable for understanding molecular mechanisms and advancing preclinical studies …

Despite continuing debate about the amyloid β‐protein (or Aβ hypothesis, new lines of
evidence from laboratories and clinics worldwide support the concept that an imbalance …

Although the prevalence of dementia continues to increase worldwide, incidence in the
western world might have decreased as a result of better vascular care and improved brain …

The amyloid hypothesis for Alzheimer's disease (AD) posits a neuron-centric, linear cascade
initiated by Aβ and leading to dementia. This direct causality is incompatible with clinical …

Alzheimer's disease is a progressive neurodegenerative disease typically presenting with
symptoms of memory loss and cognitive decline. Existing theories for the causation of this …